Annonce FDA : L'abandon progressif des tests sur les animaux \u2014 PhinC Group<\/title>\r\n <link href=\"https:\/\/fonts.googleapis.com\/css2?family=Cormorant+Garamond:ital,wght@0,300;0,400;0,600;0,700;1,300;1,400&family=Poppins:wght@300;400;500;600&display=swap\" rel=\"stylesheet\" \/>\r\n <style>\r\n *, *::before, *::after { box-sizing: border-box; margin: 0; padding: 0; }\r\n\r\n :root {\r\n --navy: #00005f;\r\n --pink: #d94b9f;\r\n --navy-light: #0a0a7a;\r\n --navy-soft: #f0f0f8;\r\n --pink-light: #fce8f4;\r\n --text: #1a1a2e;\r\n --text-muted: #5a5a7a;\r\n --white: #ffffff;\r\n --border: #ddd8ee;\r\n }\r\n\r\n html { scroll-behavior: smooth; }\r\n\r\n body {\r\n font-family: 'Poppins', sans-serif;\r\n color: var(--text);\r\n background: var(--white);\r\n font-size: 16px;\r\n line-height: 1.7;\r\n -webkit-font-smoothing: antialiased;\r\n }\r\n .midd-visual {\r\n margin-top: 0;\r\n}\r\n.midd-grid > div:last-child { margin-top: 0; padding-top: 0; }\r\n\r\n \/* \u2500\u2500 HERO \u2500\u2500 *\/\r\n .hero {\r\n background: var(--white);\r\n display: grid; grid-template-columns: 1fr 1fr;\r\n gap: 64px; align-items: center;\r\n padding: 80px 80px;\r\n border-bottom: 1px solid var(--border);\r\n }\r\n .hero-content {}\r\n .hero-kicker {\r\n font-size: 11px; font-weight: 600; letter-spacing: 3px; text-transform: uppercase;\r\n color: var(--pink); margin-bottom: 24px;\r\n display: flex; align-items: center; gap: 12px;\r\n }\r\n .hero-kicker::before {\r\n content: ''; width: 40px; height: 1px; background: var(--pink);\r\n }\r\n .hero h1 {\r\n font-family: 'Cormorant Garamond', serif;\r\n font-size: clamp(30px, 3.5vw, 52px);\r\n font-weight: 400; line-height: 1.15;\r\n color: var(--navy); max-width: 600px;\r\n margin-bottom: 24px;\r\n }\r\n .hero h1 em {\r\n font-style: normal; color: var(--pink);\r\n }\r\n .hero-sub {\r\n font-size: 15px; font-weight: 300;\r\n color: var(--text-muted);\r\n line-height: 1.7;\r\n margin-bottom: 40px;\r\n }\r\n .hero-actions { display: flex; gap: 16px; flex-wrap: wrap; }\r\n .btn-primary {\r\n background: var(--pink); color: #ffffff !important;\r\n padding: 14px 32px; border-radius: 2px;\r\n font-size: 12px; font-weight: 600; letter-spacing: 1.5px; text-transform: uppercase;\r\n text-decoration: none; transition: transform 0.25s;\r\n}\r\n.btn-primary:hover { background: var(--pink); color: #ffffff !important; transform: translateY(-2px); }\r\n .btn-outline {\r\n border: 1px solid var(--navy); color: var(--navy) !important;\r\n padding: 14px 32px; border-radius: 2px;\r\n font-size: 12px; font-weight: 400; letter-spacing: 1px;\r\n text-decoration: none; transition: all 0.25s;\r\n}\r\n.btn-outline:hover { background: var(--navy); color: #ffffff !important; }\r\n .hero-image-placeholder {\r\n width: 100%; aspect-ratio: 4\/3;\r\n background: var(--navy-soft);\r\n \r\n border-radius: 4px;\r\n display: flex; flex-direction: column;\r\n align-items: center; justify-content: center;\r\n gap: 12px; color: var(--text-muted);\r\n font-size: 13px; font-weight: 400;\r\n }\r\n .hero-image-placeholder svg { opacity: 0.35; }\r\n\r\n \/* \u2500\u2500 SECTION BASE \u2500\u2500 *\/\r\n section { padding: 96px 80px; }\r\n .section-label {\r\n font-size: 12px; font-weight: 600; letter-spacing: 3px;\r\n text-transform: uppercase; color: var(--pink);\r\n margin-bottom: 16px;\r\n }\r\n h2 {\r\n font-family: 'Cormorant Garamond', serif;\r\n font-size: clamp(44px, 4vw, 54px);\r\n font-weight: 400; line-height: 1.15;\r\n color: var(--navy); margin-bottom: 24px;\r\n }\r\n h2 span { color: var(--pink); font-style: normal; }\r\n h3 {\r\n font-family: 'Cormorant Garamond', serif;\r\n font-size: clamp(22px, 2.5vw, 30px);\r\n font-weight: 600; color: var(--navy);\r\n margin-bottom: 16px; line-height: 1.25;\r\n }\r\n p { color: var(--text-muted); margin-bottom: 20px; font-weight: 300; }\r\n p:last-child { margin-bottom: 0; }\r\n\r\n \/* \u2500\u2500 INTRO STRIP \u2500\u2500 *\/\r\n .intro-strip {\r\n background: var(--navy-soft);\r\n padding: 56px 80px;\r\n display: grid; grid-template-columns: 1fr 1fr;\r\n gap: 48px; align-items: center;\r\n }\r\n .intro-strip .big-quote {\r\n font-family: 'Cormorant Garamond', serif;\r\n font-size: clamp(22px, 3vw, 36px);\r\n font-weight: 300; color: var(--navy);\r\n line-height: 1.3; font-style: italic;\r\n }\r\n .intro-strip .big-quote strong {\r\n color: var(--pink); font-style: normal; font-weight: 600;\r\n }\r\n .intro-date {\r\n font-size: 11px; font-weight: 600; letter-spacing: 2px;\r\n text-transform: uppercase; color: var(--pink);\r\n margin-bottom: 12px;\r\n }\r\n\r\n \/* \u2500\u2500 CONTEXT SECTION \u2500\u2500 *\/\r\n .context-section {\r\n background: var(--white);\r\n display: grid; grid-template-columns: 1fr 2fr; gap: 80px; align-items: start;\r\n }\r\n .context-sticky { position: sticky; top: 100px; }\r\n .stat-block {\r\n border-left: 3px solid var(--pink);\r\n padding-left: 20px; margin-bottom: 36px;\r\n }\r\n .stat-number {\r\n font-family: 'Cormorant Garamond', serif;\r\n font-size: 56px; font-weight: 300; color: var(--navy);\r\n line-height: 1;\r\n }\r\n .stat-label { font-size: 13px; color: var(--text-muted); font-weight: 400; }\r\n\r\n \/* \u2500\u2500 CARDS GRID \u2500\u2500 *\/\r\n .cards-section { background: var(--navy); }\r\n .cards-section h2 { color: var(--white); }\r\n .cards-section .section-label { color: var(--pink); }\r\n .cards-section p { color: rgba(255,255,255,0.6); }\r\n .cards-grid {\r\n display: grid; grid-template-columns: repeat(3, 1fr); gap: 2px;\r\n margin-top: 56px;\r\n }\r\n .card {\r\n background: rgba(255,255,255,0.04);\r\n padding: 40px 32px; border-top: 3px solid transparent;\r\n transition: all 0.3s; cursor: default;\r\n }\r\n .card:hover { background: rgba(255,255,255,0.08); border-top-color: var(--pink); }\r\n .card-icon {\r\n width: 48px; height: 48px; border-radius: 50%;\r\n background: rgba(217,75,159,0.15);\r\n display: flex; align-items: center; justify-content: center;\r\n margin-bottom: 24px; font-size: 20px;\r\n }\r\n .card h3 { color: var(--white); font-size: 20px; margin-bottom: 12px; }\r\n .card p { color: rgba(255,255,255,0.55); font-size: 14px; }\r\n\r\n \/* \u2500\u2500 TIMELINE \u2500\u2500 *\/\r\n .timeline-section { background: var(--white); }\r\n .timeline {\r\n margin-top: 64px; position: relative;\r\n padding-left: 48px;\r\n }\r\n .timeline::before {\r\n content: ''; position: absolute; left: 0; top: 8px;\r\n width: 2px; height: calc(100% - 16px);\r\n background: linear-gradient(to bottom, var(--pink), var(--navy));\r\n }\r\n .timeline-item { position: relative; margin-bottom: 56px; }\r\n .timeline-item:last-child { margin-bottom: 0; }\r\n .timeline-dot {\r\n position: absolute; left: -52px; top: 6px;\r\n width: 12px; height: 12px; border-radius: 50%;\r\n background: var(--pink); border: 2px solid var(--white);\r\n box-shadow: 0 0 0 3px var(--pink);\r\n }\r\n .timeline-year {\r\n font-size: 11px; font-weight: 600; letter-spacing: 2px;\r\n text-transform: uppercase; color: var(--pink); margin-bottom: 8px;\r\n }\r\n .timeline-item h3 { font-size: 20px; margin-bottom: 10px; }\r\n\r\n \/* \u2500\u2500 SPLIT SECTION \u2500\u2500 *\/\r\n .split-section {\r\n display: grid; grid-template-columns: 1fr 1fr;\r\n gap: 0; background: var(--white);\r\n padding: 0;\r\n }\r\n .split-col {\r\n padding: 96px 72px;\r\n }\r\n .split-col:first-child { background: var(--navy-soft); }\r\n .split-col:last-child { background: var(--pink-light); }\r\n .split-col h3 { font-size: clamp(22px, 2vw, 28px); margin-bottom: 20px; }\r\n\r\n \/* \u2500\u2500 MIDD SECTION \u2500\u2500 *\/\r\n .midd-section { background: linear-gradient(135deg, #00003a, #00005f); }\r\n .midd-section h2 { color: var(--white); }\r\n .midd-section .section-label { color: var(--pink); }\r\n .midd-grid {\r\n display: grid; grid-template-columns: 1fr 1fr; gap: 48px;\r\n margin-top: 56px; align-items: start;\r\n }\r\n .midd-text p { color: rgba(255,255,255,0.65); }\r\n .midd-text h3 { color: var(--white); font-size: 22px; margin-top: 32px; margin-bottom: 12px; }\r\n .midd-text h3:first-child { margin-top: 0; }\r\n .midd-pills { display: flex; flex-wrap: wrap; gap: 8px; margin-top: 32px; }\r\n .pill {\r\n padding: 8px 18px; border-radius: 40px;\r\n border: 1px solid rgba(217,75,159,0.4);\r\n font-size: 12px; font-weight: 500; color: rgba(255,255,255,0.75);\r\n letter-spacing: 0.5px;\r\n }\r\n .pill.active { background: var(--pink); border-color: var(--pink); color: var(--white); }\r\n .midd-visual {\r\n background: rgba(255,255,255,0.04);\r\n border: 1px solid rgba(255,255,255,0.1);\r\n border-radius: 4px; padding: 40px;\r\n }\r\n .midd-visual h3 { color: var(--white); font-size: 20px; margin-bottom: 28px; }\r\n .flow-item {\r\n display: flex; gap: 16px; align-items: flex-start;\r\n margin-bottom: 20px; padding-bottom: 20px;\r\n border-bottom: 1px solid rgba(255,255,255,0.08);\r\n }\r\n .flow-item:last-child { border-bottom: none; margin-bottom: 0; padding-bottom: 0; }\r\n .flow-num {\r\n width: 28px; height: 28px; border-radius: 50%;\r\n background: var(--pink); color: var(--white);\r\n font-size: 12px; font-weight: 600;\r\n display: flex; align-items: center; justify-content: center;\r\n flex-shrink: 0; margin-top: 2px;\r\n }\r\n .flow-label { font-size: 14px; color: rgba(255,255,255,0.6); }\r\n .flow-title { font-size: 15px; font-weight: 500; color: var(--white); margin-bottom: 4px; }\r\n\r\n \/* \u2500\u2500 MODELS TABLE \u2500\u2500 *\/\r\n .models-section { background: var(--white); }\r\n .models-table { margin-top: 56px; width: 100%; border-collapse: collapse; }\r\n .models-table thead th {\r\n background: var(--navy); color: var(--white);\r\n padding: 16px 20px; text-align: left;\r\n font-size: 12px; font-weight: 600; letter-spacing: 1px; text-transform: uppercase;\r\n }\r\n .models-table tbody tr { border-bottom: 1px solid var(--border); }\r\n .models-table tbody tr:hover { background: var(--navy-soft); }\r\n .models-table tbody td { padding: 18px 20px; font-size: 14px; color: var(--text-muted); }\r\n .models-table tbody td:first-child { font-weight: 500; color: var(--navy); }\r\n .badge {\r\n display: inline-block; padding: 3px 10px; border-radius: 40px;\r\n font-size: 11px; font-weight: 600; letter-spacing: 0.5px;\r\n }\r\n .badge-high { background: #e8f5e9; color: #2e7d32; }\r\n .badge-med { background: #fff3e0; color: #e65100; }\r\n .badge-emerg{ background: var(--pink-light); color: var(--pink); }\r\n\r\n \/* \u2500\u2500 QUOTE SECTION \u2500\u2500 *\/\r\n .quote-section {\r\n background: var(--navy-soft);\r\n text-align: center; padding: 80px 120px;\r\n }\r\n .big-blockquote {\r\n font-family: 'Cormorant Garamond', serif;\r\n font-size: clamp(26px, 3.5vw, 44px);\r\n font-weight: 300; color: var(--navy);\r\n line-height: 1.3; font-style: italic;\r\n max-width: 900px; margin: 0 auto 24px;\r\n }\r\n .big-blockquote strong { font-style: normal; color: var(--pink); }\r\n .quote-source {\r\n font-size: 13px; color: var(--text-muted); letter-spacing: 1px;\r\n }\r\n\r\n \/* \u2500\u2500 OPPORTUNITIES \u2500\u2500 *\/\r\n .opps-section { background: var(--white); }\r\n .opps-grid {\r\n display: grid; grid-template-columns: repeat(2, 1fr); gap: 32px;\r\n margin-top: 56px;\r\n }\r\n .opp-card {\r\n border: 1px solid var(--border); padding: 36px;\r\n position: relative; overflow: hidden;\r\n transition: border-color 0.3s;\r\n }\r\n .opp-card::before {\r\n content: ''; position: absolute; top: 0; left: 0;\r\n width: 4px; height: 100%; background: var(--pink);\r\n }\r\n .opp-card:hover { border-color: var(--pink); }\r\n .opp-card h3 { font-size: 20px; margin-bottom: 12px; }\r\n\r\n \/* \u2500\u2500 CTA SECTION \u2500\u2500 *\/\r\n .cta-section {\r\n background: linear-gradient(160deg, var(--navy) 0%, #0a006a 100%);\r\n text-align: center; padding: 112px 80px;\r\n position: relative; overflow: hidden;\r\n }\r\n .cta-section::before {\r\n content: '';\r\n position: absolute; inset: 0;\r\n background: radial-gradient(ellipse 50% 80% at 50% 50%, rgba(217,75,159,0.15), transparent);\r\n }\r\n .cta-section > * { position: relative; }\r\n .cta-eyebrow {\r\n font-size: 11px; font-weight: 600; letter-spacing: 3px;\r\n text-transform: uppercase; color: var(--pink); margin-bottom: 20px;\r\n }\r\n .cta-section h2 {\r\n color: var(--white); font-size: clamp(36px, 5vw, 64px);\r\n max-width: 800px; margin: 0 auto 20px;\r\n }\r\n .cta-section h2 span { color: var(--pink); }\r\n .cta-section p {\r\n color: rgba(255,255,255,0.6); max-width: 520px; margin: 0 auto 48px;\r\n }\r\n .cta-section .btn-primary { font-size: 14px; padding: 18px 48px; }\r\n\r\n\r\n \/* \u2500\u2500 RESPONSIVE \u2500\u2500 *\/\r\n @media (max-width: 900px) {\r\n section, nav { padding-left: 24px; padding-right: 24px; }\r\n .hero { padding: 100px 24px 60px; }\r\n .intro-strip, .context-section, .split-section, .midd-grid, .opps-grid { grid-template-columns: 1fr; }\r\n .cards-grid { grid-template-columns: 1fr; }\r\n .quote-section { padding: 60px 24px; }\r\n .cta-section { padding: 80px 24px; }\r\n .hero { grid-template-columns: 1fr; padding: 48px 24px; }\r\n }\r\n <\/style>\r\n<\/head>\r\n<body>\r\n\r\n \r\n <section class=\"hero\">\r\n <div class=\"hero-content\">\r\n <div class=\"hero-kicker\">FDA Modernization Act 2.0<\/div>\r\n <h1>\r\n A guide to the FDA announcement to phase out animal testing<br>\r\n <em style=\"font-size:0.5em; line-height:1.3; display:block; margin-top:8px;\">The Next Era in Preclinical Drug Development using Non-Animal Models and Pharmacometrics<\/em>\r\n <\/h1>\r\n <p class=\"hero-sub\">\r\n The landscape of preclinical drug development is undergoing a paradigm shift driven by the need for more human-relevant evidence and a global regulatory movement toward ethical safety testing.\r\n <\/p>\r\n <div class=\"hero-actions\">\r\n <a href=\"#intro\" class=\"btn-primary\">Learn more<\/a>\r\n <a href=\"https:\/\/www.phinc-group.com\/en\/contact\/\" class=\"btn-outline\">Get in touch<\/a>\r\n <\/div>\r\n <\/div>\r\n <div class=\"hero-image-placeholder\">\r\n <img decoding=\"async\" src=\"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/06\/FDA-Approval-MIDD-File.png\" alt=\"FDA MIDD - PhinC Group\" style=\"width:100%; height:100%; object-fit:cover; border-radius:4px;\" \/>\r\n <\/div>\r\n <\/section>\r\n\r\n\r\n \r\n <div class=\"intro-strip\" id=\"intro\">\r\n <div>\r\n <div class=\"section-label\">Context<\/div>\r\n <h2>A major<br>paradigm <span>shift<\/span><\/h2>\r\n <\/div>\r\n <div>\r\n <p>The passage of the FDA Modernization Act 2.0 in December 2022 was a watershed moment that removed the statutory requirement for animal studies to be the sole path to first-in-human clinical trials (Najjar et al., 2023).<\/p>\r\n <p>This legislation explicitly permits the use of Non-Animal Models (NAMs), such as cell-based assays and microphysiological systems (MPS), synergistically paired with pharmacometrics, specifically Physiologically Based Pharmacokinetic (PBPK) and Pharmacokinetic\/Pharmacodynamic (PK\/PD) modeling. Together, these quantitative tools assess drug safety and efficacy when scientifically justified (Garc\u00eda, n.d.).<\/p>\r\n <p>This transition transcends ethical compliance; it addresses the high attrition rates in drug development caused by the poor translational predictivity of traditional animal models (Paliwal et al., 2020; Sun et al., 2022). By relying on mechanistically rich, human-centered approaches driven by Model-Informed Drug Development (MIDD), the industry is entering an era of accelerated, precise, and more reliable predictive toxicology and pharmacology.<\/p>\r\n <\/div>\r\n <\/div>\r\n\r\n\r\n \r\n <section class=\"context-section\" id=\"prochaine-ere\">\r\n <div class=\"context-sticky\">\r\n <div class=\"section-label\">Next era<\/div>\r\n <h2 class=\"translation-block\">of Preclinical Drug Development<\/h2>\r\n <\/div>\r\n <div>\r\n <p>Historically, animal testing has been crucial for making go\/no-go decisions at major transition points in the drug pipeline. However, safety and efficacy failures remain major causes of attrition in drug discovery, highlighting the limitations of non-human species in mimicking human pathophysiology (Goldring, n.d.). \n\nThis is especially true for highly targeted therapies, such as cell and gene therapies or advanced biologics, which rely on precise interactions with human-specific receptors and tissue microenvironments that animal models often fail to capture (Santos, n.d.).<\/p>\r\n <p>NAMs and pharmacometrics bridge this translational gap by utilizing a quantitative, data-driven framework.<\/p>\r\n <\/div>\r\n <\/section>\r\n\r\n\r\n \r\n <section class=\"cards-section\" id=\"nams\">\r\n <div class=\"section-label\">New Approach Methodologies<\/div>\r\n <h2>tools that<br><span>fill the translational gap<\/span><\/h2>\r\n <div class=\"cards-grid\">\r\n <div class=\"card\">\r\n <div class=\"card-icon\">\u2697\ufe0f<\/div>\r\n <h3><em>In-vitro<\/em> and In-chemico Methods<\/h3>\r\n <p>Complex cell-based assays that evaluate the biological and toxicological effects of substances at a cellular level, providing the raw parameters (e.g., intrinsic clearance, receptor affinity) needed for computational models.<\/p>\r\n <\/div>\r\n <div class=\"card\">\r\n <div class=\"card-icon\">\ud83d\udd2c<\/div>\r\n <h3>Microphysiological Systems (MPS)<\/h3>\r\n <p>Often known as organs-on-a-chip, these advanced cellular models mimic human organ interactions. For example, multi-organ chips (e.g., skin-liver-thyroid) can incorporate exposure routes and metabolism, generating highly accurate human-specific data to feed into predictive models (Najjar et al., 2023).<\/p>\r\n <\/div>\r\n <div class=\"card\">\r\n <div class=\"card-icon\">\ud83d\udcbb<\/div>\r\n <h3>Pharmacometrics and <em>In-silico<\/em> Modeling<\/h3>\r\n <p>The mathematical engine translating bench data to human predictions: PBPK Modeling, Quantitative Systems Pharmacology (QSP), PK\/PD Modeling. These frameworks enable the robust extrapolation of in-vitro concentration-response readouts to in vivo human dose-response predictions, ensuring next-generation risk assessment (NGRA) (Najjar et al., 2023).<\/p>\r\n <\/div>\r\n <\/div>\r\n <\/section>\r\n\r\n\r\n \r\n <section class=\"midd-section\" id=\"midd\">\r\n <div class=\"section-label\">Pharmacometrics and <em>In-silico<\/em> Modeling<\/div>\r\n <h2 style=\"color:white\" class=\"translation-block\">The mathematical engine <br>of the new preclinical era<\/h2>\r\n <div class=\"midd-grid\">\r\n <div class=\"midd-text\">\r\n <h3>PBPK Modeling<\/h3>\r\n <p>Integrates physiological mechanisms (blood flow, organ volumes) with drug-specific chemical properties to predict how a drug will be absorbed, distributed, metabolized, and excreted (ADME) in humans, completely bypassing the need for allometric scaling from animals.<\/p>\r\n <h3>PK\/PD Modeling<\/h3>\r\n <p>Links to the predicted drug exposure (PK) to the biological response or toxicity (PD) over time.<\/p>\r\n <h3>Quantitative Systems Pharmacology (QSP)<\/h3>\r\n <p>Evaluates mechanistically how a drug interacts with biological pathways to predict toxic events (Goldring, n.d.).<\/p>\r\n <div class=\"midd-pills\">\r\n <a href=\"\/en\/service\/pbpk\/\" class=\"pill active\">PBPK<\/a>\r\n <a href=\"\/en\/service\/poppk-pd\/\" class=\"pill active\">PK\/PD<\/a>\r\n <a href=\"\/en\/QSP\/\" class=\"pill active\">QSP<\/a>\r\n \r\n <a href=\"\/en\/midd\/\" class=\"pill active\">MIDD<\/a>\r\n \r\n <span class=\"pill\">Allometric scaling<\/span>\r\n <span class=\"pill\">ADME<\/span>\r\n <\/div>\r\n <\/div>\r\n <div style=\"align-self:start; margin-top:0;\">\r\n <div class=\"midd-visual\">\r\n <h3 class=\"translation-block\">From <em>in vitro<\/em> to <em>in vivo <\/em> in humans<\/h3>\r\n <div class=\"flow-item\">\r\n <div class=\"flow-num\">1<\/div>\r\n <div>\r\n <div class=\"flow-title translation-block\"><em>In vitro<\/em> & in-chemico data<\/div>\r\n <div class=\"flow-label\">Intrinsic clearance, receptor affinity, raw ADME parameters<\/div>\r\n <\/div>\r\n <\/div>\r\n <div class=\"flow-item\">\r\n <div class=\"flow-num\">2<\/div>\r\n <div>\r\n <div class=\"flow-title\">MPS (organ-on-a-chip) data<\/div>\r\n <div class=\"flow-label\">Exposure routes, metabolism, highly precise human-specific data<\/div>\r\n <\/div>\r\n <\/div>\r\n <div class=\"flow-item\">\r\n <div class=\"flow-num\">3<\/div>\r\n <div>\r\n <div class=\"flow-title\">PBPK Model<\/div>\r\n <div class=\"flow-label\">Integration of human physiological mechanisms \u2014 ADME prediction without animal extrapolation<\/div>\r\n <\/div>\r\n <\/div>\r\n <div class=\"flow-item\">\r\n <div class=\"flow-num\">4<\/div>\r\n <div>\r\n <div class=\"flow-title\">PK\/PD Modeling & QSP<\/div>\r\n <div class=\"flow-label\">Exposure \u2192 biological response; mechanistic biological pathways<\/div>\r\n <\/div>\r\n <\/div>\r\n <div class=\"flow-item\">\r\n <div class=\"flow-num\">5<\/div>\r\n <div>\r\n <div class=\"flow-title\">Next Generation Risk Assessment (NGRA)<\/div>\r\n <div class=\"flow-label translation-block\">Robust in vitro concentration-response to in vivo dose-response extrapolation in humans<\/div>\r\n <\/div>\r\n <\/div>\r\n <\/div>\r\n <\/div>\r\n <\/div>\r\n <\/section>\r\n\r\n\r\n \r\n <section class=\"timeline-section\" id=\"precedents\">\r\n <div class=\"section-label\">Global Precedents<\/div>\r\n <h2 class=\"translation-block\">Minimizing animal testing: <br><span>an international effort<\/span><\/h2>\r\n <p style=\"max-width:680px; color:var(--text-muted); font-weight:300;\">While the FDA Modernization Act 2.0 is a significant milestone in the United States, it builds upon decades of global precedents anchored by the 3Rs principles: Replacement, Reduction, and Refinement of animal use (Santos, n.d.).<\/p>\r\n <div class=\"timeline\">\r\n <div class=\"timeline-item\">\r\n <div class=\"timeline-dot\"><\/div>\r\n <div class=\"timeline-year\">United States - December 2022<\/div>\r\n <h3>FDA Modernization Act 2.0<\/h3>\r\n <p>Removal of the legal requirement to conduct animal studies as the sole pathway to human clinical trials. Explicit authorization of NAMs, cell-based assays, MPS, PBPK, and PK\/PD when scientifically justified (Najjar et al., 2023).<\/p>\r\n <\/div>\r\n <div class=\"timeline-item\">\r\n <div class=\"timeline-dot\"><\/div>\r\n <div class=\"timeline-year\">European Union<\/div>\r\n <h3>Operating under Directive 2010\/63\/EU<\/h3>\r\n <p>Europe has been a pioneer in minimizing animal testing, highlighted by the 2013 ban on animal testing for cosmetics. Agencies such as the European Medicines Agency (EMA) actively champion MIDD and are revising guidelines to facilitate the regulatory acceptance of 3R approaches and NAM-generated data (Courtot, n.d.).<\/p>\r\n <\/div>\r\n <div class=\"timeline-item\">\r\n <div class=\"timeline-dot\"><\/div>\r\n <div class=\"timeline-year\">United Kingdom<\/div>\r\n <h3>Strategic plan for phased elimination<\/h3>\r\n <p>The UK recently published an ambitious strategic plan to phase out animal testing, aiming to integrate NAMs and in silico methods systematically across regulatory frameworks (Courtot, n.d.).<\/p>\r\n <\/div>\r\n <\/div>\r\n <\/section>\r\n\r\n\r\n \r\n <section class=\"opps-section\" id=\"implications\">\r\n <div class=\"section-label\">Implications<\/div>\r\n <h2 class=\"translation-block\">For drug development,<br>regulatory strategy and <span>alternative methods<\/span><\/h2>\r\n <p style=\"color:var(--text-muted); font-weight:300; margin-bottom:0;\">The FDA's openness to NAMs signifies that regulatory agencies are receptive to non-animal evidence, provided it is \"fit-for-purpose\" and scientifically robust (Garc\u00eda, n.d.).<\/p>\r\n <div class=\"opps-grid\" style=\"margin-top:48px;\">\r\n <div class=\"opp-card\">\r\n <h3>1. Drug Development Strategy<\/h3>\r\n <p>Sponsors must transition from purely descriptive assays to mechanistic, model-based approaches. By integrating organoids and PBPK\/PD modeling early in the pipeline, developers can simulate clinical scenarios in-silico. This allows teams to identify toxic liabilities, optimize formulation behavior, and accurately predict First-In-Human (FIH) starting doses before progressing to expensive clinical trials (Garc\u00eda, n.d.).<\/p>\r\n <\/div>\r\n <div class=\"opp-card\">\r\n <h3>2. Regulatory Strategy<\/h3>\r\n <p>The goal of regulatory agencies is not to lower the safety bar but to promote better, mathematically justified science. Sponsors seeking to leverage NAMs must demonstrate the physiological relevance, predictive performance, and validation status of their chosen models (Garc\u00eda, n.d.). Early engagement through mechanisms like the FDA\u2019s MIDD Paired Meeting Program or the EMA's Innovation Task Force is critical. Regulators increasingly expect to see how in vitro data inputs into PBPK models to justify safety margins prior to marketing authorization application (MAA) submissions (Courtot, n.d.).<\/p>\r\n <\/div>\r\n <div class=\"opp-card\">\r\n <h3>3. Non-Animal Models (NAMs) Integration<\/h3>\r\n <p>NAMs will complement rather than immediately displace the entirety of the classical biopharmaceutic toolkit. Their implementation requires rigorous standardization to ensure they can credibly replace, reduce, or refine animal studies. Pharmacometrics acts as a crucial bridge translating static in-vitro NAM results into dynamic in vivo human predictions without compromising human safety (Garc\u00eda, n.d.).<\/p>\r\n <\/div>\r\n <\/div>\r\n <\/section>\r\n\r\n\r\n \r\n <section class=\"models-section\" id=\"comparaison\">\r\n <div class=\"section-label\">Comparison table<\/div>\r\n <h2 class=\"translation-block\">Traditional Models vs. <br><span>NAMs & Pharmacometrics <\/span><\/h2>\r\n <table class=\"models-table\">\r\n <thead>\r\n <tr>\r\n <th>Feature<\/th>\r\n <th>Traditional Animal Models<\/th>\r\n <th>NAMs + Pharmacometrics (PBPK & PK\/PD)<\/th>\r\n <\/tr>\r\n <\/thead>\r\n <tbody>\r\n <tr>\r\n <td>Physiological Relevance<\/td>\r\n <td>Limited due to cross-species differences.<\/td>\r\n <td>High; utilizes human cells, tissues, and exact human physiological parameters.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td>Dose Prediction & Scaling<\/td>\r\n <td>Relies on empirical allometric scaling; often inaccurate.<\/td>\r\n <td>Uses mechanistic PBPK modeling for highly accurate human dose predictions.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td>Cost & Throughput<\/td>\r\n <td>High cost, low throughput, resource intensive.<\/td>\r\n <td>Decreasing in-vitro costs, rapid in silico throughput capabilities.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td>Mechanism of Action (MoA)<\/td>\r\n <td>Often observational and descriptive.<\/td>\r\n <td>Highly mechanistic, linking molecular insights directly to simulated systemic outcomes.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td>Ethical Compliance<\/td>\r\n <td>High concern; increasingly restricted globally.<\/td>\r\n <td>Fully aligned with the 3Rs (Replacement, Reduction, Refinement).<\/td>\r\n <\/tr>\r\n <\/tbody>\r\n <\/table>\r\n <\/section>\r\n\r\n\r\n \r\n <section class=\"timeline-section\" id=\"references\" style=\"padding-top:64px; padding-bottom:64px;\">\r\n <div class=\"section-label\">References<\/div>\r\n <h2>Sources<\/h2>\r\n <div style=\"margin-top:32px; display:flex; flex-direction:column; gap:12px;\">\r\n <p style=\"font-size:14px; border-left:3px solid var(--border); padding-left:16px; margin:0;\">Courtot, L. (n.d.). <em>NAMs In France And Europe: The Current Landscape.<\/em> Drug Discovery Online. (Posted on 20th March 2026). <a href=\"https:\/\/www.drugdiscoveryonline.com\/doc\/nams-in-france-and-europe-the-current-landscape-0001\" target=\"_blank\" rel=\"noopener\" style=\"color:var(--accent, #d94b9f);\">See article<\/a><\/p>\r\n <p style=\"font-size:14px; border-left:3px solid var(--border); padding-left:16px; margin:0;\">Garc\u00eda, M. A. (25th April 2026). <em>Application of New Approach Methodologies to Improve Oral Biopharmaceutic Assessments.<\/em> MDPI. <a href=\"https:\/\/www.mdpi.com\/1999-4923\/18\/5\/552\" target=\"_blank\" rel=\"noopener\" style=\"color:var(--accent, #d94b9f);\">See article<\/a><\/p>\r\n <p style=\"font-size:14px; border-left:3px solid var(--border); padding-left:16px; margin:0;\">Goldring, C. E. (n.d.). <em>Quantitative systems toxicology: modelling to mechanistically understand and predict drug safety.<\/em> University of Liverpool Repository. (Deposited on 28th October 2025 ; modified on 23rd May 2026). <a href=\"https:\/\/livrepository.liverpool.ac.uk\/3195045\/\" target=\"_blank\" rel=\"noopener\" style=\"color:var(--accent, #d94b9f);\">See article<\/a><\/p>\r\n <p style=\"font-size:14px; border-left:3px solid var(--border); padding-left:16px; margin:0;\">Najjar, A., Kramer, N., Gardner, I., Hartung, T., & Steger-Hartmann, T. (2023). <em>Editorial: Advances in and applications of predictive toxicology: 2022.<\/em> Frontiers in Pharmacology, 14. <a href=\"https:\/\/www.frontiersin.org\/journals\/pharmacology\/articles\/10.3389\/fphar.2023.1257423\/full\" target=\"_blank\" rel=\"noopener\" style=\"color:var(--accent, #d94b9f);\">See article<\/a><\/p>\r\n <p style=\"font-size:14px; border-left:3px solid var(--border); padding-left:16px; margin:0;\">Santos, J. A. (n.d.). <em>New Approach Methods In Practice: Where Are We Today.<\/em> Drug Discovery Online. (Article posted on the 10th of February 2026). <a href=\"https:\/\/www.drugdiscoveryonline.com\/doc\/new-approach-methods-in-practice-where-are-we-today-0001\" target=\"_blank\" rel=\"noopener\" style=\"color:var(--accent, #d94b9f);\">See article<\/a><\/p>\r\n <\/div>\r\n <\/section>\r\n\r\n\r\n \r\n <section class=\"cta-section\">\r\n <div class=\"cta-eyebrow\">PhinC Group \u00b7 MIDD Experts<\/div>\r\n <h2>Stop Guessing. <span>Start Modeling.<\/span><\/h2>\r\n <p>The transition to non-animal methods is underway. Our pharmacometrics teams help position your development program at the forefront of this transformation<\/p>\r\n <a href=\"https:\/\/www.phinc-group.com\/en\/contact\/\" class=\"btn-primary\">Tell us about your program<\/a>\r\n <\/section>\r\n\r\n\r\n\r\n<\/body>\r\n<\/html>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>The landscape of preclinical drug development is undergoing a paradigm shift driven by the need for more human-relevant evidence and a global regulatory movement toward ethical safety testing.<\/p>","protected":false},"author":2,"featured_media":5071,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"elementor_header_footer","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[40],"tags":[],"service-associe":[],"class_list":["post-5066","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"acf":[],"yoast_head":"\n<title>Guide de l'annonce de la FDA sur l'abandon progressif des tests sur les animaux - PhinC Group<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.phinc-group.com\/en\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Guide de l'annonce de la FDA sur l'abandon progressif des tests sur les animaux - PhinC Group\" \/>\n<meta property=\"og:description\" content=\"Le paysage du d\u00e9veloppement pr\u00e9clinique des m\u00e9dicaments subit un changement de paradigme majeur, motiv\u00e9 par le besoin de donn\u00e9es plus pertinentes pour l'homme et par un mouvement r\u00e9glementaire mondial en faveur de tests d'innocuit\u00e9 \u00e9thiques.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.phinc-group.com\/en\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\/\" \/>\n<meta property=\"og:site_name\" content=\"PhinC Group\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-26T11:13:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-20T13:04:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/06\/FDA-Approval-MIDD-File-e1783337522541.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Mohamed Taourirt\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mohamed Taourirt\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\\\/\"},\"author\":{\"name\":\"Mohamed Taourirt\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#\\\/schema\\\/person\\\/4c52ff6996589ff3ca1ec2882fc5dd0a\"},\"headline\":\"Guide de l’annonce de la FDA sur l’abandon progressif des tests sur les animaux\",\"datePublished\":\"2026-06-26T11:13:29+00:00\",\"dateModified\":\"2026-07-20T13:04:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\\\/\"},\"wordCount\":1903,\"publisher\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/FDA-Approval-MIDD-File-e1783337522541.png\",\"articleSection\":[\"Insights\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\\\/\",\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\\\/\",\"name\":\"Guide de l'annonce de la FDA sur l'abandon progressif des tests sur les animaux - PhinC Group\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/FDA-Approval-MIDD-File-e1783337522541.png\",\"datePublished\":\"2026-06-26T11:13:29+00:00\",\"dateModified\":\"2026-07-20T13:04:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.phinc-group.com\\\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/FDA-Approval-MIDD-File-e1783337522541.png\",\"contentUrl\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/FDA-Approval-MIDD-File-e1783337522541.png\",\"width\":800,\"height\":600},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.phinc-group.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Guide de l’annonce de la FDA sur l’abandon progressif des tests sur les animaux\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/\",\"name\":\"PhinC Group\",\"description\":\"Quantitative Pharmacology Solutions & Modeling\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#organization\",\"name\":\"PhinC Group\",\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/Icone-PhinC-New_white-600px.jpg\",\"contentUrl\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/Icone-PhinC-New_white-600px.jpg\",\"width\":600,\"height\":600,\"caption\":\"PhinC Group\"},\"image\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#\\\/schema\\\/person\\\/4c52ff6996589ff3ca1ec2882fc5dd0a\",\"name\":\"Mohamed Taourirt\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g\",\"caption\":\"Mohamed Taourirt\"},\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/en\\\/author\\\/mtaourirt\\\/\"}]}<\/script>\n","yoast_head_json":{"title":"Guide de l'annonce de la FDA sur l'abandon progressif des tests sur les animaux - PhinC Group","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.phinc-group.com\/en\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\/","og_locale":"en_US","og_type":"article","og_title":"Guide de l'annonce de la FDA sur l'abandon progressif des tests sur les animaux - PhinC Group","og_description":"Le paysage du d\u00e9veloppement pr\u00e9clinique des m\u00e9dicaments subit un changement de paradigme majeur, motiv\u00e9 par le besoin de donn\u00e9es plus pertinentes pour l'homme et par un mouvement r\u00e9glementaire mondial en faveur de tests d'innocuit\u00e9 \u00e9thiques.","og_url":"https:\/\/www.phinc-group.com\/en\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\/","og_site_name":"PhinC Group","article_published_time":"2026-06-26T11:13:29+00:00","article_modified_time":"2026-07-20T13:04:02+00:00","og_image":[{"width":800,"height":600,"url":"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/06\/FDA-Approval-MIDD-File-e1783337522541.png","type":"image\/png"}],"author":"Mohamed Taourirt","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Mohamed Taourirt","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.phinc-group.com\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\/#article","isPartOf":{"@id":"https:\/\/www.phinc-group.com\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\/"},"author":{"name":"Mohamed Taourirt","@id":"https:\/\/www.phinc-group.com\/fr\/#\/schema\/person\/4c52ff6996589ff3ca1ec2882fc5dd0a"},"headline":"Guide de l’annonce de la FDA sur l’abandon progressif des tests sur les animaux","datePublished":"2026-06-26T11:13:29+00:00","dateModified":"2026-07-20T13:04:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.phinc-group.com\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\/"},"wordCount":1903,"publisher":{"@id":"https:\/\/www.phinc-group.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.phinc-group.com\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/06\/FDA-Approval-MIDD-File-e1783337522541.png","articleSection":["Insights"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.phinc-group.com\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\/","url":"https:\/\/www.phinc-group.com\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\/","name":"Guide de l'annonce de la FDA sur l'abandon progressif des tests sur les animaux - PhinC Group","isPartOf":{"@id":"https:\/\/www.phinc-group.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.phinc-group.com\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\/#primaryimage"},"image":{"@id":"https:\/\/www.phinc-group.com\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/06\/FDA-Approval-MIDD-File-e1783337522541.png","datePublished":"2026-06-26T11:13:29+00:00","dateModified":"2026-07-20T13:04:02+00:00","breadcrumb":{"@id":"https:\/\/www.phinc-group.com\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.phinc-group.com\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.phinc-group.com\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\/#primaryimage","url":"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/06\/FDA-Approval-MIDD-File-e1783337522541.png","contentUrl":"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/06\/FDA-Approval-MIDD-File-e1783337522541.png","width":800,"height":600},{"@type":"BreadcrumbList","@id":"https:\/\/www.phinc-group.com\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.phinc-group.com\/en\/"},{"@type":"ListItem","position":2,"name":"Guide de l’annonce de la FDA sur l’abandon progressif des tests sur les animaux"}]},{"@type":"WebSite","@id":"https:\/\/www.phinc-group.com\/fr\/#website","url":"https:\/\/www.phinc-group.com\/fr\/","name":"PhinC Group","description":"Quantitative Pharmacology Solutions & Modeling","publisher":{"@id":"https:\/\/www.phinc-group.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.phinc-group.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.phinc-group.com\/fr\/#organization","name":"PhinC Group","url":"https:\/\/www.phinc-group.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.phinc-group.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2025\/01\/Icone-PhinC-New_white-600px.jpg","contentUrl":"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2025\/01\/Icone-PhinC-New_white-600px.jpg","width":600,"height":600,"caption":"PhinC Group"},"image":{"@id":"https:\/\/www.phinc-group.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.phinc-group.com\/fr\/#\/schema\/person\/4c52ff6996589ff3ca1ec2882fc5dd0a","name":"Mohamed Taourirt","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g","caption":"Mohamed Taourirt"},"url":"https:\/\/www.phinc-group.com\/en\/author\/mtaourirt\/"}]}},"_links":{"self":[{"href":"https:\/\/www.phinc-group.com\/en\/wp-json\/wp\/v2\/posts\/5066","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.phinc-group.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.phinc-group.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.phinc-group.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.phinc-group.com\/en\/wp-json\/wp\/v2\/comments?post=5066"}],"version-history":[{"count":24,"href":"https:\/\/www.phinc-group.com\/en\/wp-json\/wp\/v2\/posts\/5066\/revisions"}],"predecessor-version":[{"id":5105,"href":"https:\/\/www.phinc-group.com\/en\/wp-json\/wp\/v2\/posts\/5066\/revisions\/5105"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.phinc-group.com\/en\/wp-json\/wp\/v2\/media\/5071"}],"wp:attachment":[{"href":"https:\/\/www.phinc-group.com\/en\/wp-json\/wp\/v2\/media?parent=5066"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.phinc-group.com\/en\/wp-json\/wp\/v2\/categories?post=5066"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.phinc-group.com\/en\/wp-json\/wp\/v2\/tags?post=5066"},{"taxonomy":"service-associe","embeddable":true,"href":"https:\/\/www.phinc-group.com\/en\/wp-json\/wp\/v2\/service-associe?post=5066"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

\n\t\t\t\t

\n\t\t\t\t\t\r\n\r\n\r\n \r\n \r\n Annonce FDA : L'abandon progressif des tests sur les animaux \u2014 PhinC Group<\/title>\r\n <link href=\"https:\/\/fonts.googleapis.com\/css2?family=Cormorant+Garamond:ital,wght@0,300;0,400;0,600;0,700;1,300;1,400&family=Poppins:wght@300;400;500;600&display=swap\" rel=\"stylesheet\" \/>\r\n <style>\r\n *, *::before, *::after { box-sizing: border-box; margin: 0; padding: 0; }\r\n\r\n :root {\r\n --navy: #00005f;\r\n --pink: #d94b9f;\r\n --navy-light: #0a0a7a;\r\n --navy-soft: #f0f0f8;\r\n --pink-light: #fce8f4;\r\n --text: #1a1a2e;\r\n --text-muted: #5a5a7a;\r\n --white: #ffffff;\r\n --border: #ddd8ee;\r\n }\r\n\r\n html { scroll-behavior: smooth; }\r\n\r\n body {\r\n font-family: 'Poppins', sans-serif;\r\n color: var(--text);\r\n background: var(--white);\r\n font-size: 16px;\r\n line-height: 1.7;\r\n -webkit-font-smoothing: antialiased;\r\n }\r\n .midd-visual {\r\n margin-top: 0;\r\n}\r\n.midd-grid > div:last-child { margin-top: 0; padding-top: 0; }\r\n\r\n \/* \u2500\u2500 HERO \u2500\u2500 *\/\r\n .hero {\r\n background: var(--white);\r\n display: grid; grid-template-columns: 1fr 1fr;\r\n gap: 64px; align-items: center;\r\n padding: 80px 80px;\r\n border-bottom: 1px solid var(--border);\r\n }\r\n .hero-content {}\r\n .hero-kicker {\r\n font-size: 11px; font-weight: 600; letter-spacing: 3px; text-transform: uppercase;\r\n color: var(--pink); margin-bottom: 24px;\r\n display: flex; align-items: center; gap: 12px;\r\n }\r\n .hero-kicker::before {\r\n content: ''; width: 40px; height: 1px; background: var(--pink);\r\n }\r\n .hero h1 {\r\n font-family: 'Cormorant Garamond', serif;\r\n font-size: clamp(30px, 3.5vw, 52px);\r\n font-weight: 400; line-height: 1.15;\r\n color: var(--navy); max-width: 600px;\r\n margin-bottom: 24px;\r\n }\r\n .hero h1 em {\r\n font-style: normal; color: var(--pink);\r\n }\r\n .hero-sub {\r\n font-size: 15px; font-weight: 300;\r\n color: var(--text-muted);\r\n line-height: 1.7;\r\n margin-bottom: 40px;\r\n }\r\n .hero-actions { display: flex; gap: 16px; flex-wrap: wrap; }\r\n .btn-primary {\r\n background: var(--pink); color: #ffffff !important;\r\n padding: 14px 32px; border-radius: 2px;\r\n font-size: 12px; font-weight: 600; letter-spacing: 1.5px; text-transform: uppercase;\r\n text-decoration: none; transition: transform 0.25s;\r\n}\r\n.btn-primary:hover { background: var(--pink); color: #ffffff !important; transform: translateY(-2px); }\r\n .btn-outline {\r\n border: 1px solid var(--navy); color: var(--navy) !important;\r\n padding: 14px 32px; border-radius: 2px;\r\n font-size: 12px; font-weight: 400; letter-spacing: 1px;\r\n text-decoration: none; transition: all 0.25s;\r\n}\r\n.btn-outline:hover { background: var(--navy); color: #ffffff !important; }\r\n .hero-image-placeholder {\r\n width: 100%; aspect-ratio: 4\/3;\r\n background: var(--navy-soft);\r\n \r\n border-radius: 4px;\r\n display: flex; flex-direction: column;\r\n align-items: center; justify-content: center;\r\n gap: 12px; color: var(--text-muted);\r\n font-size: 13px; font-weight: 400;\r\n }\r\n .hero-image-placeholder svg { opacity: 0.35; }\r\n\r\n \/* \u2500\u2500 SECTION BASE \u2500\u2500 *\/\r\n section { padding: 96px 80px; }\r\n .section-label {\r\n font-size: 12px; font-weight: 600; letter-spacing: 3px;\r\n text-transform: uppercase; color: var(--pink);\r\n margin-bottom: 16px;\r\n }\r\n h2 {\r\n font-family: 'Cormorant Garamond', serif;\r\n font-size: clamp(44px, 4vw, 54px);\r\n font-weight: 400; line-height: 1.15;\r\n color: var(--navy); margin-bottom: 24px;\r\n }\r\n h2 span { color: var(--pink); font-style: normal; }\r\n h3 {\r\n font-family: 'Cormorant Garamond', serif;\r\n font-size: clamp(22px, 2.5vw, 30px);\r\n font-weight: 600; color: var(--navy);\r\n margin-bottom: 16px; line-height: 1.25;\r\n }\r\n p { color: var(--text-muted); margin-bottom: 20px; font-weight: 300; }\r\n p:last-child { margin-bottom: 0; }\r\n\r\n \/* \u2500\u2500 INTRO STRIP \u2500\u2500 *\/\r\n .intro-strip {\r\n background: var(--navy-soft);\r\n padding: 56px 80px;\r\n display: grid; grid-template-columns: 1fr 1fr;\r\n gap: 48px; align-items: center;\r\n }\r\n .intro-strip .big-quote {\r\n font-family: 'Cormorant Garamond', serif;\r\n font-size: clamp(22px, 3vw, 36px);\r\n font-weight: 300; color: var(--navy);\r\n line-height: 1.3; font-style: italic;\r\n }\r\n .intro-strip .big-quote strong {\r\n color: var(--pink); font-style: normal; font-weight: 600;\r\n }\r\n .intro-date {\r\n font-size: 11px; font-weight: 600; letter-spacing: 2px;\r\n text-transform: uppercase; color: var(--pink);\r\n margin-bottom: 12px;\r\n }\r\n\r\n \/* \u2500\u2500 CONTEXT SECTION \u2500\u2500 *\/\r\n .context-section {\r\n background: var(--white);\r\n display: grid; grid-template-columns: 1fr 2fr; gap: 80px; align-items: start;\r\n }\r\n .context-sticky { position: sticky; top: 100px; }\r\n .stat-block {\r\n border-left: 3px solid var(--pink);\r\n padding-left: 20px; margin-bottom: 36px;\r\n }\r\n .stat-number {\r\n font-family: 'Cormorant Garamond', serif;\r\n font-size: 56px; font-weight: 300; color: var(--navy);\r\n line-height: 1;\r\n }\r\n .stat-label { font-size: 13px; color: var(--text-muted); font-weight: 400; }\r\n\r\n \/* \u2500\u2500 CARDS GRID \u2500\u2500 *\/\r\n .cards-section { background: var(--navy); }\r\n .cards-section h2 { color: var(--white); }\r\n .cards-section .section-label { color: var(--pink); }\r\n .cards-section p { color: rgba(255,255,255,0.6); }\r\n .cards-grid {\r\n display: grid; grid-template-columns: repeat(3, 1fr); gap: 2px;\r\n margin-top: 56px;\r\n }\r\n .card {\r\n background: rgba(255,255,255,0.04);\r\n padding: 40px 32px; border-top: 3px solid transparent;\r\n transition: all 0.3s; cursor: default;\r\n }\r\n .card:hover { background: rgba(255,255,255,0.08); border-top-color: var(--pink); }\r\n .card-icon {\r\n width: 48px; height: 48px; border-radius: 50%;\r\n background: rgba(217,75,159,0.15);\r\n display: flex; align-items: center; justify-content: center;\r\n margin-bottom: 24px; font-size: 20px;\r\n }\r\n .card h3 { color: var(--white); font-size: 20px; margin-bottom: 12px; }\r\n .card p { color: rgba(255,255,255,0.55); font-size: 14px; }\r\n\r\n \/* \u2500\u2500 TIMELINE \u2500\u2500 *\/\r\n .timeline-section { background: var(--white); }\r\n .timeline {\r\n margin-top: 64px; position: relative;\r\n padding-left: 48px;\r\n }\r\n .timeline::before {\r\n content: ''; position: absolute; left: 0; top: 8px;\r\n width: 2px; height: calc(100% - 16px);\r\n background: linear-gradient(to bottom, var(--pink), var(--navy));\r\n }\r\n .timeline-item { position: relative; margin-bottom: 56px; }\r\n .timeline-item:last-child { margin-bottom: 0; }\r\n .timeline-dot {\r\n position: absolute; left: -52px; top: 6px;\r\n width: 12px; height: 12px; border-radius: 50%;\r\n background: var(--pink); border: 2px solid var(--white);\r\n box-shadow: 0 0 0 3px var(--pink);\r\n }\r\n .timeline-year {\r\n font-size: 11px; font-weight: 600; letter-spacing: 2px;\r\n text-transform: uppercase; color: var(--pink); margin-bottom: 8px;\r\n }\r\n .timeline-item h3 { font-size: 20px; margin-bottom: 10px; }\r\n\r\n \/* \u2500\u2500 SPLIT SECTION \u2500\u2500 *\/\r\n .split-section {\r\n display: grid; grid-template-columns: 1fr 1fr;\r\n gap: 0; background: var(--white);\r\n padding: 0;\r\n }\r\n .split-col {\r\n padding: 96px 72px;\r\n }\r\n .split-col:first-child { background: var(--navy-soft); }\r\n .split-col:last-child { background: var(--pink-light); }\r\n .split-col h3 { font-size: clamp(22px, 2vw, 28px); margin-bottom: 20px; }\r\n\r\n \/* \u2500\u2500 MIDD SECTION \u2500\u2500 *\/\r\n .midd-section { background: linear-gradient(135deg, #00003a, #00005f); }\r\n .midd-section h2 { color: var(--white); }\r\n .midd-section .section-label { color: var(--pink); }\r\n .midd-grid {\r\n display: grid; grid-template-columns: 1fr 1fr; gap: 48px;\r\n margin-top: 56px; align-items: start;\r\n }\r\n .midd-text p { color: rgba(255,255,255,0.65); }\r\n .midd-text h3 { color: var(--white); font-size: 22px; margin-top: 32px; margin-bottom: 12px; }\r\n .midd-text h3:first-child { margin-top: 0; }\r\n .midd-pills { display: flex; flex-wrap: wrap; gap: 8px; margin-top: 32px; }\r\n .pill {\r\n padding: 8px 18px; border-radius: 40px;\r\n border: 1px solid rgba(217,75,159,0.4);\r\n font-size: 12px; font-weight: 500; color: rgba(255,255,255,0.75);\r\n letter-spacing: 0.5px;\r\n }\r\n .pill.active { background: var(--pink); border-color: var(--pink); color: var(--white); }\r\n .midd-visual {\r\n background: rgba(255,255,255,0.04);\r\n border: 1px solid rgba(255,255,255,0.1);\r\n border-radius: 4px; padding: 40px;\r\n }\r\n .midd-visual h3 { color: var(--white); font-size: 20px; margin-bottom: 28px; }\r\n .flow-item {\r\n display: flex; gap: 16px; align-items: flex-start;\r\n margin-bottom: 20px; padding-bottom: 20px;\r\n border-bottom: 1px solid rgba(255,255,255,0.08);\r\n }\r\n .flow-item:last-child { border-bottom: none; margin-bottom: 0; padding-bottom: 0; }\r\n .flow-num {\r\n width: 28px; height: 28px; border-radius: 50%;\r\n background: var(--pink); color: var(--white);\r\n font-size: 12px; font-weight: 600;\r\n display: flex; align-items: center; justify-content: center;\r\n flex-shrink: 0; margin-top: 2px;\r\n }\r\n .flow-label { font-size: 14px; color: rgba(255,255,255,0.6); }\r\n .flow-title { font-size: 15px; font-weight: 500; color: var(--white); margin-bottom: 4px; }\r\n\r\n \/* \u2500\u2500 MODELS TABLE \u2500\u2500 *\/\r\n .models-section { background: var(--white); }\r\n .models-table { margin-top: 56px; width: 100%; border-collapse: collapse; }\r\n .models-table thead th {\r\n background: var(--navy); color: var(--white);\r\n padding: 16px 20px; text-align: left;\r\n font-size: 12px; font-weight: 600; letter-spacing: 1px; text-transform: uppercase;\r\n }\r\n .models-table tbody tr { border-bottom: 1px solid var(--border); }\r\n .models-table tbody tr:hover { background: var(--navy-soft); }\r\n .models-table tbody td { padding: 18px 20px; font-size: 14px; color: var(--text-muted); }\r\n .models-table tbody td:first-child { font-weight: 500; color: var(--navy); }\r\n .badge {\r\n display: inline-block; padding: 3px 10px; border-radius: 40px;\r\n font-size: 11px; font-weight: 600; letter-spacing: 0.5px;\r\n }\r\n .badge-high { background: #e8f5e9; color: #2e7d32; }\r\n .badge-med { background: #fff3e0; color: #e65100; }\r\n .badge-emerg{ background: var(--pink-light); color: var(--pink); }\r\n\r\n \/* \u2500\u2500 QUOTE SECTION \u2500\u2500 *\/\r\n .quote-section {\r\n background: var(--navy-soft);\r\n text-align: center; padding: 80px 120px;\r\n }\r\n .big-blockquote {\r\n font-family: 'Cormorant Garamond', serif;\r\n font-size: clamp(26px, 3.5vw, 44px);\r\n font-weight: 300; color: var(--navy);\r\n line-height: 1.3; font-style: italic;\r\n max-width: 900px; margin: 0 auto 24px;\r\n }\r\n .big-blockquote strong { font-style: normal; color: var(--pink); }\r\n .quote-source {\r\n font-size: 13px; color: var(--text-muted); letter-spacing: 1px;\r\n }\r\n\r\n \/* \u2500\u2500 OPPORTUNITIES \u2500\u2500 *\/\r\n .opps-section { background: var(--white); }\r\n .opps-grid {\r\n display: grid; grid-template-columns: repeat(2, 1fr); gap: 32px;\r\n margin-top: 56px;\r\n }\r\n .opp-card {\r\n border: 1px solid var(--border); padding: 36px;\r\n position: relative; overflow: hidden;\r\n transition: border-color 0.3s;\r\n }\r\n .opp-card::before {\r\n content: ''; position: absolute; top: 0; left: 0;\r\n width: 4px; height: 100%; background: var(--pink);\r\n }\r\n .opp-card:hover { border-color: var(--pink); }\r\n .opp-card h3 { font-size: 20px; margin-bottom: 12px; }\r\n\r\n \/* \u2500\u2500 CTA SECTION \u2500\u2500 *\/\r\n .cta-section {\r\n background: linear-gradient(160deg, var(--navy) 0%, #0a006a 100%);\r\n text-align: center; padding: 112px 80px;\r\n position: relative; overflow: hidden;\r\n }\r\n .cta-section::before {\r\n content: '';\r\n position: absolute; inset: 0;\r\n background: radial-gradient(ellipse 50% 80% at 50% 50%, rgba(217,75,159,0.15), transparent);\r\n }\r\n .cta-section > * { position: relative; }\r\n .cta-eyebrow {\r\n font-size: 11px; font-weight: 600; letter-spacing: 3px;\r\n text-transform: uppercase; color: var(--pink); margin-bottom: 20px;\r\n }\r\n .cta-section h2 {\r\n color: var(--white); font-size: clamp(36px, 5vw, 64px);\r\n max-width: 800px; margin: 0 auto 20px;\r\n }\r\n .cta-section h2 span { color: var(--pink); }\r\n .cta-section p {\r\n color: rgba(255,255,255,0.6); max-width: 520px; margin: 0 auto 48px;\r\n }\r\n .cta-section .btn-primary { font-size: 14px; padding: 18px 48px; }\r\n\r\n\r\n \/* \u2500\u2500 RESPONSIVE \u2500\u2500 *\/\r\n @media (max-width: 900px) {\r\n section, nav { padding-left: 24px; padding-right: 24px; }\r\n .hero { padding: 100px 24px 60px; }\r\n .intro-strip, .context-section, .split-section, .midd-grid, .opps-grid { grid-template-columns: 1fr; }\r\n .cards-grid { grid-template-columns: 1fr; }\r\n .quote-section { padding: 60px 24px; }\r\n .cta-section { padding: 80px 24px; }\r\n .hero { grid-template-columns: 1fr; padding: 48px 24px; }\r\n }\r\n <\/style>\r\n<\/head>\r\n<body>\r\n\r\n \r\n <section class=\"hero\">\r\n <div class=\"hero-content\">\r\n <div class=\"hero-kicker\">FDA Modernization Act 2.0<\/div>\r\n <h1>\r\n A guide to the FDA announcement to phase out animal testing<br>\r\n <em style=\"font-size:0.5em; line-height:1.3; display:block; margin-top:8px;\">The Next Era in Preclinical Drug Development using Non-Animal Models and Pharmacometrics<\/em>\r\n <\/h1>\r\n <p class=\"hero-sub\">\r\n The landscape of preclinical drug development is undergoing a paradigm shift driven by the need for more human-relevant evidence and a global regulatory movement toward ethical safety testing.\r\n <\/p>\r\n <div class=\"hero-actions\">\r\n <a href=\"#intro\" class=\"btn-primary\">Learn more<\/a>\r\n <a href=\"https:\/\/www.phinc-group.com\/en\/contact\/\" class=\"btn-outline\">Get in touch<\/a>\r\n <\/div>\r\n <\/div>\r\n <div class=\"hero-image-placeholder\">\r\n <img decoding=\"async\" src=\"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/06\/FDA-Approval-MIDD-File.png\" alt=\"FDA MIDD - PhinC Group\" style=\"width:100%; height:100%; object-fit:cover; border-radius:4px;\" \/>\r\n <\/div>\r\n <\/section>\r\n\r\n\r\n \r\n <div class=\"intro-strip\" id=\"intro\">\r\n <div>\r\n <div class=\"section-label\">Context<\/div>\r\n <h2>A major<br>paradigm <span>shift<\/span><\/h2>\r\n <\/div>\r\n <div>\r\n <p>The passage of the FDA Modernization Act 2.0 in December 2022 was a watershed moment that removed the statutory requirement for animal studies to be the sole path to first-in-human clinical trials (Najjar et al., 2023).<\/p>\r\n <p>This legislation explicitly permits the use of Non-Animal Models (NAMs), such as cell-based assays and microphysiological systems (MPS), synergistically paired with pharmacometrics, specifically Physiologically Based Pharmacokinetic (PBPK) and Pharmacokinetic\/Pharmacodynamic (PK\/PD) modeling. Together, these quantitative tools assess drug safety and efficacy when scientifically justified (Garc\u00eda, n.d.).<\/p>\r\n <p>This transition transcends ethical compliance; it addresses the high attrition rates in drug development caused by the poor translational predictivity of traditional animal models (Paliwal et al., 2020; Sun et al., 2022). By relying on mechanistically rich, human-centered approaches driven by Model-Informed Drug Development (MIDD), the industry is entering an era of accelerated, precise, and more reliable predictive toxicology and pharmacology.<\/p>\r\n <\/div>\r\n <\/div>\r\n\r\n\r\n \r\n <section class=\"context-section\" id=\"prochaine-ere\">\r\n <div class=\"context-sticky\">\r\n <div class=\"section-label\">Next era<\/div>\r\n <h2 class=\"translation-block\">of Preclinical Drug Development<\/h2>\r\n <\/div>\r\n <div>\r\n <p>Historically, animal testing has been crucial for making go\/no-go decisions at major transition points in the drug pipeline. However, safety and efficacy failures remain major causes of attrition in drug discovery, highlighting the limitations of non-human species in mimicking human pathophysiology (Goldring, n.d.). \n\nThis is especially true for highly targeted therapies, such as cell and gene therapies or advanced biologics, which rely on precise interactions with human-specific receptors and tissue microenvironments that animal models often fail to capture (Santos, n.d.).<\/p>\r\n <p>NAMs and pharmacometrics bridge this translational gap by utilizing a quantitative, data-driven framework.<\/p>\r\n <\/div>\r\n <\/section>\r\n\r\n\r\n \r\n <section class=\"cards-section\" id=\"nams\">\r\n <div class=\"section-label\">New Approach Methodologies<\/div>\r\n <h2>tools that<br><span>fill the translational gap<\/span><\/h2>\r\n <div class=\"cards-grid\">\r\n <div class=\"card\">\r\n <div class=\"card-icon\">\u2697\ufe0f<\/div>\r\n <h3><em>In-vitro<\/em> and In-chemico Methods<\/h3>\r\n <p>Complex cell-based assays that evaluate the biological and toxicological effects of substances at a cellular level, providing the raw parameters (e.g., intrinsic clearance, receptor affinity) needed for computational models.<\/p>\r\n <\/div>\r\n <div class=\"card\">\r\n <div class=\"card-icon\">\ud83d\udd2c<\/div>\r\n <h3>Microphysiological Systems (MPS)<\/h3>\r\n <p>Often known as organs-on-a-chip, these advanced cellular models mimic human organ interactions. For example, multi-organ chips (e.g., skin-liver-thyroid) can incorporate exposure routes and metabolism, generating highly accurate human-specific data to feed into predictive models (Najjar et al., 2023).<\/p>\r\n <\/div>\r\n <div class=\"card\">\r\n <div class=\"card-icon\">\ud83d\udcbb<\/div>\r\n <h3>Pharmacometrics and <em>In-silico<\/em> Modeling<\/h3>\r\n <p>The mathematical engine translating bench data to human predictions: PBPK Modeling, Quantitative Systems Pharmacology (QSP), PK\/PD Modeling. These frameworks enable the robust extrapolation of in-vitro concentration-response readouts to in vivo human dose-response predictions, ensuring next-generation risk assessment (NGRA) (Najjar et al., 2023).<\/p>\r\n <\/div>\r\n <\/div>\r\n <\/section>\r\n\r\n\r\n \r\n <section class=\"midd-section\" id=\"midd\">\r\n <div class=\"section-label\">Pharmacometrics and <em>In-silico<\/em> Modeling<\/div>\r\n <h2 style=\"color:white\" class=\"translation-block\">The mathematical engine <br>of the new preclinical era<\/h2>\r\n <div class=\"midd-grid\">\r\n <div class=\"midd-text\">\r\n <h3>PBPK Modeling<\/h3>\r\n <p>Integrates physiological mechanisms (blood flow, organ volumes) with drug-specific chemical properties to predict how a drug will be absorbed, distributed, metabolized, and excreted (ADME) in humans, completely bypassing the need for allometric scaling from animals.<\/p>\r\n <h3>PK\/PD Modeling<\/h3>\r\n <p>Links to the predicted drug exposure (PK) to the biological response or toxicity (PD) over time.<\/p>\r\n <h3>Quantitative Systems Pharmacology (QSP)<\/h3>\r\n <p>Evaluates mechanistically how a drug interacts with biological pathways to predict toxic events (Goldring, n.d.).<\/p>\r\n <div class=\"midd-pills\">\r\n <a href=\"\/en\/service\/pbpk\/\" class=\"pill active\">PBPK<\/a>\r\n <a href=\"\/en\/service\/poppk-pd\/\" class=\"pill active\">PK\/PD<\/a>\r\n <a href=\"\/en\/QSP\/\" class=\"pill active\">QSP<\/a>\r\n \r\n <a href=\"\/en\/midd\/\" class=\"pill active\">MIDD<\/a>\r\n \r\n <span class=\"pill\">Allometric scaling<\/span>\r\n <span class=\"pill\">ADME<\/span>\r\n <\/div>\r\n <\/div>\r\n <div style=\"align-self:start; margin-top:0;\">\r\n <div class=\"midd-visual\">\r\n <h3 class=\"translation-block\">From <em>in vitro<\/em> to <em>in vivo <\/em> in humans<\/h3>\r\n <div class=\"flow-item\">\r\n <div class=\"flow-num\">1<\/div>\r\n <div>\r\n <div class=\"flow-title translation-block\"><em>In vitro<\/em> & in-chemico data<\/div>\r\n <div class=\"flow-label\">Intrinsic clearance, receptor affinity, raw ADME parameters<\/div>\r\n <\/div>\r\n <\/div>\r\n <div class=\"flow-item\">\r\n <div class=\"flow-num\">2<\/div>\r\n <div>\r\n <div class=\"flow-title\">MPS (organ-on-a-chip) data<\/div>\r\n <div class=\"flow-label\">Exposure routes, metabolism, highly precise human-specific data<\/div>\r\n <\/div>\r\n <\/div>\r\n <div class=\"flow-item\">\r\n <div class=\"flow-num\">3<\/div>\r\n <div>\r\n <div class=\"flow-title\">PBPK Model<\/div>\r\n <div class=\"flow-label\">Integration of human physiological mechanisms \u2014 ADME prediction without animal extrapolation<\/div>\r\n <\/div>\r\n <\/div>\r\n <div class=\"flow-item\">\r\n <div class=\"flow-num\">4<\/div>\r\n <div>\r\n <div class=\"flow-title\">PK\/PD Modeling & QSP<\/div>\r\n <div class=\"flow-label\">Exposure \u2192 biological response; mechanistic biological pathways<\/div>\r\n <\/div>\r\n <\/div>\r\n <div class=\"flow-item\">\r\n <div class=\"flow-num\">5<\/div>\r\n <div>\r\n <div class=\"flow-title\">Next Generation Risk Assessment (NGRA)<\/div>\r\n <div class=\"flow-label translation-block\">Robust in vitro concentration-response to in vivo dose-response extrapolation in humans<\/div>\r\n <\/div>\r\n <\/div>\r\n <\/div>\r\n <\/div>\r\n <\/div>\r\n <\/section>\r\n\r\n\r\n \r\n <section class=\"timeline-section\" id=\"precedents\">\r\n <div class=\"section-label\">Global Precedents<\/div>\r\n <h2 class=\"translation-block\">Minimizing animal testing: <br><span>an international effort<\/span><\/h2>\r\n <p style=\"max-width:680px; color:var(--text-muted); font-weight:300;\">While the FDA Modernization Act 2.0 is a significant milestone in the United States, it builds upon decades of global precedents anchored by the 3Rs principles: Replacement, Reduction, and Refinement of animal use (Santos, n.d.).<\/p>\r\n <div class=\"timeline\">\r\n <div class=\"timeline-item\">\r\n <div class=\"timeline-dot\"><\/div>\r\n <div class=\"timeline-year\">United States - December 2022<\/div>\r\n <h3>FDA Modernization Act 2.0<\/h3>\r\n <p>Removal of the legal requirement to conduct animal studies as the sole pathway to human clinical trials. Explicit authorization of NAMs, cell-based assays, MPS, PBPK, and PK\/PD when scientifically justified (Najjar et al., 2023).<\/p>\r\n <\/div>\r\n <div class=\"timeline-item\">\r\n <div class=\"timeline-dot\"><\/div>\r\n <div class=\"timeline-year\">European Union<\/div>\r\n <h3>Operating under Directive 2010\/63\/EU<\/h3>\r\n <p>Europe has been a pioneer in minimizing animal testing, highlighted by the 2013 ban on animal testing for cosmetics. Agencies such as the European Medicines Agency (EMA) actively champion MIDD and are revising guidelines to facilitate the regulatory acceptance of 3R approaches and NAM-generated data (Courtot, n.d.).<\/p>\r\n <\/div>\r\n <div class=\"timeline-item\">\r\n <div class=\"timeline-dot\"><\/div>\r\n <div class=\"timeline-year\">United Kingdom<\/div>\r\n <h3>Strategic plan for phased elimination<\/h3>\r\n <p>The UK recently published an ambitious strategic plan to phase out animal testing, aiming to integrate NAMs and in silico methods systematically across regulatory frameworks (Courtot, n.d.).<\/p>\r\n <\/div>\r\n <\/div>\r\n <\/section>\r\n\r\n\r\n \r\n <section class=\"opps-section\" id=\"implications\">\r\n <div class=\"section-label\">Implications<\/div>\r\n <h2 class=\"translation-block\">For drug development,<br>regulatory strategy and <span>alternative methods<\/span><\/h2>\r\n <p style=\"color:var(--text-muted); font-weight:300; margin-bottom:0;\">The FDA's openness to NAMs signifies that regulatory agencies are receptive to non-animal evidence, provided it is \"fit-for-purpose\" and scientifically robust (Garc\u00eda, n.d.).<\/p>\r\n <div class=\"opps-grid\" style=\"margin-top:48px;\">\r\n <div class=\"opp-card\">\r\n <h3>1. Drug Development Strategy<\/h3>\r\n <p>Sponsors must transition from purely descriptive assays to mechanistic, model-based approaches. By integrating organoids and PBPK\/PD modeling early in the pipeline, developers can simulate clinical scenarios in-silico. This allows teams to identify toxic liabilities, optimize formulation behavior, and accurately predict First-In-Human (FIH) starting doses before progressing to expensive clinical trials (Garc\u00eda, n.d.).<\/p>\r\n <\/div>\r\n <div class=\"opp-card\">\r\n <h3>2. Regulatory Strategy<\/h3>\r\n <p>The goal of regulatory agencies is not to lower the safety bar but to promote better, mathematically justified science. Sponsors seeking to leverage NAMs must demonstrate the physiological relevance, predictive performance, and validation status of their chosen models (Garc\u00eda, n.d.). Early engagement through mechanisms like the FDA\u2019s MIDD Paired Meeting Program or the EMA's Innovation Task Force is critical. Regulators increasingly expect to see how in vitro data inputs into PBPK models to justify safety margins prior to marketing authorization application (MAA) submissions (Courtot, n.d.).<\/p>\r\n <\/div>\r\n <div class=\"opp-card\">\r\n <h3>3. Non-Animal Models (NAMs) Integration<\/h3>\r\n <p>NAMs will complement rather than immediately displace the entirety of the classical biopharmaceutic toolkit. Their implementation requires rigorous standardization to ensure they can credibly replace, reduce, or refine animal studies. Pharmacometrics acts as a crucial bridge translating static in-vitro NAM results into dynamic in vivo human predictions without compromising human safety (Garc\u00eda, n.d.).<\/p>\r\n <\/div>\r\n <\/div>\r\n <\/section>\r\n\r\n\r\n \r\n <section class=\"models-section\" id=\"comparaison\">\r\n <div class=\"section-label\">Comparison table<\/div>\r\n <h2 class=\"translation-block\">Traditional Models vs. <br><span>NAMs & Pharmacometrics <\/span><\/h2>\r\n <table class=\"models-table\">\r\n <thead>\r\n <tr>\r\n <th>Feature<\/th>\r\n <th>Traditional Animal Models<\/th>\r\n <th>NAMs + Pharmacometrics (PBPK & PK\/PD)<\/th>\r\n <\/tr>\r\n <\/thead>\r\n <tbody>\r\n <tr>\r\n <td>Physiological Relevance<\/td>\r\n <td>Limited due to cross-species differences.<\/td>\r\n <td>High; utilizes human cells, tissues, and exact human physiological parameters.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td>Dose Prediction & Scaling<\/td>\r\n <td>Relies on empirical allometric scaling; often inaccurate.<\/td>\r\n <td>Uses mechanistic PBPK modeling for highly accurate human dose predictions.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td>Cost & Throughput<\/td>\r\n <td>High cost, low throughput, resource intensive.<\/td>\r\n <td>Decreasing in-vitro costs, rapid in silico throughput capabilities.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td>Mechanism of Action (MoA)<\/td>\r\n <td>Often observational and descriptive.<\/td>\r\n <td>Highly mechanistic, linking molecular insights directly to simulated systemic outcomes.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td>Ethical Compliance<\/td>\r\n <td>High concern; increasingly restricted globally.<\/td>\r\n <td>Fully aligned with the 3Rs (Replacement, Reduction, Refinement).<\/td>\r\n <\/tr>\r\n <\/tbody>\r\n <\/table>\r\n <\/section>\r\n\r\n\r\n \r\n <section class=\"timeline-section\" id=\"references\" style=\"padding-top:64px; padding-bottom:64px;\">\r\n <div class=\"section-label\">References<\/div>\r\n <h2>Sources<\/h2>\r\n <div style=\"margin-top:32px; display:flex; flex-direction:column; gap:12px;\">\r\n <p style=\"font-size:14px; border-left:3px solid var(--border); padding-left:16px; margin:0;\">Courtot, L. (n.d.). <em>NAMs In France And Europe: The Current Landscape.<\/em> Drug Discovery Online. (Posted on 20th March 2026). <a href=\"https:\/\/www.drugdiscoveryonline.com\/doc\/nams-in-france-and-europe-the-current-landscape-0001\" target=\"_blank\" rel=\"noopener\" style=\"color:var(--accent, #d94b9f);\">See article<\/a><\/p>\r\n <p style=\"font-size:14px; border-left:3px solid var(--border); padding-left:16px; margin:0;\">Garc\u00eda, M. A. (25th April 2026). <em>Application of New Approach Methodologies to Improve Oral Biopharmaceutic Assessments.<\/em> MDPI. <a href=\"https:\/\/www.mdpi.com\/1999-4923\/18\/5\/552\" target=\"_blank\" rel=\"noopener\" style=\"color:var(--accent, #d94b9f);\">See article<\/a><\/p>\r\n <p style=\"font-size:14px; border-left:3px solid var(--border); padding-left:16px; margin:0;\">Goldring, C. E. (n.d.). <em>Quantitative systems toxicology: modelling to mechanistically understand and predict drug safety.<\/em> University of Liverpool Repository. (Deposited on 28th October 2025 ; modified on 23rd May 2026). <a href=\"https:\/\/livrepository.liverpool.ac.uk\/3195045\/\" target=\"_blank\" rel=\"noopener\" style=\"color:var(--accent, #d94b9f);\">See article<\/a><\/p>\r\n <p style=\"font-size:14px; border-left:3px solid var(--border); padding-left:16px; margin:0;\">Najjar, A., Kramer, N., Gardner, I., Hartung, T., & Steger-Hartmann, T. (2023). <em>Editorial: Advances in and applications of predictive toxicology: 2022.<\/em> Frontiers in Pharmacology, 14. <a href=\"https:\/\/www.frontiersin.org\/journals\/pharmacology\/articles\/10.3389\/fphar.2023.1257423\/full\" target=\"_blank\" rel=\"noopener\" style=\"color:var(--accent, #d94b9f);\">See article<\/a><\/p>\r\n <p style=\"font-size:14px; border-left:3px solid var(--border); padding-left:16px; margin:0;\">Santos, J. A. (n.d.). <em>New Approach Methods In Practice: Where Are We Today.<\/em> Drug Discovery Online. (Article posted on the 10th of February 2026). <a href=\"https:\/\/www.drugdiscoveryonline.com\/doc\/new-approach-methods-in-practice-where-are-we-today-0001\" target=\"_blank\" rel=\"noopener\" style=\"color:var(--accent, #d94b9f);\">See article<\/a><\/p>\r\n <\/div>\r\n <\/section>\r\n\r\n\r\n \r\n <section class=\"cta-section\">\r\n <div class=\"cta-eyebrow\">PhinC Group \u00b7 MIDD Experts<\/div>\r\n <h2>Stop Guessing. <span>Start Modeling.<\/span><\/h2>\r\n <p>The transition to non-animal methods is underway. Our pharmacometrics teams help position your development program at the forefront of this transformation<\/p>\r\n <a href=\"https:\/\/www.phinc-group.com\/en\/contact\/\" class=\"btn-primary\">Tell us about your program<\/a>\r\n <\/section>\r\n\r\n\r\n\r\n<\/body>\r\n<\/html>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>The landscape of preclinical drug development is undergoing a paradigm shift driven by the need for more human-relevant evidence and a global regulatory movement toward ethical safety testing.<\/p>","protected":false},"author":2,"featured_media":5071,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"elementor_header_footer","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[40],"tags":[],"service-associe":[],"class_list":["post-5066","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"acf":[],"yoast_head":"\n<title>Guide de l'annonce de la FDA sur l'abandon progressif des tests sur les animaux - PhinC Group<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.phinc-group.com\/en\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Guide de l'annonce de la FDA sur l'abandon progressif des tests sur les animaux - PhinC Group\" \/>\n<meta property=\"og:description\" content=\"Le paysage du d\u00e9veloppement pr\u00e9clinique des m\u00e9dicaments subit un changement de paradigme majeur, motiv\u00e9 par le besoin de donn\u00e9es plus pertinentes pour l'homme et par un mouvement r\u00e9glementaire mondial en faveur de tests d'innocuit\u00e9 \u00e9thiques.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.phinc-group.com\/en\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\/\" \/>\n<meta property=\"og:site_name\" content=\"PhinC Group\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-26T11:13:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-20T13:04:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/06\/FDA-Approval-MIDD-File-e1783337522541.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Mohamed Taourirt\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mohamed Taourirt\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\\\/\"},\"author\":{\"name\":\"Mohamed Taourirt\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#\\\/schema\\\/person\\\/4c52ff6996589ff3ca1ec2882fc5dd0a\"},\"headline\":\"Guide de l’annonce de la FDA sur l’abandon progressif des tests sur les animaux\",\"datePublished\":\"2026-06-26T11:13:29+00:00\",\"dateModified\":\"2026-07-20T13:04:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\\\/\"},\"wordCount\":1903,\"publisher\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/FDA-Approval-MIDD-File-e1783337522541.png\",\"articleSection\":[\"Insights\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\\\/\",\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\\\/\",\"name\":\"Guide de l'annonce de la FDA sur l'abandon progressif des tests sur les animaux - PhinC Group\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/FDA-Approval-MIDD-File-e1783337522541.png\",\"datePublished\":\"2026-06-26T11:13:29+00:00\",\"dateModified\":\"2026-07-20T13:04:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.phinc-group.com\\\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/FDA-Approval-MIDD-File-e1783337522541.png\",\"contentUrl\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/FDA-Approval-MIDD-File-e1783337522541.png\",\"width\":800,\"height\":600},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.phinc-group.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Guide de l’annonce de la FDA sur l’abandon progressif des tests sur les animaux\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/\",\"name\":\"PhinC Group\",\"description\":\"Quantitative Pharmacology Solutions & Modeling\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#organization\",\"name\":\"PhinC Group\",\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/Icone-PhinC-New_white-600px.jpg\",\"contentUrl\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/Icone-PhinC-New_white-600px.jpg\",\"width\":600,\"height\":600,\"caption\":\"PhinC Group\"},\"image\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#\\\/schema\\\/person\\\/4c52ff6996589ff3ca1ec2882fc5dd0a\",\"name\":\"Mohamed Taourirt\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g\",\"caption\":\"Mohamed Taourirt\"},\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/en\\\/author\\\/mtaourirt\\\/\"}]}<\/script>\n","yoast_head_json":{"title":"Guide de l'annonce de la FDA sur l'abandon progressif des tests sur les animaux - PhinC Group","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.phinc-group.com\/en\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\/","og_locale":"en_US","og_type":"article","og_title":"Guide de l'annonce de la FDA sur l'abandon progressif des tests sur les animaux - PhinC Group","og_description":"Le paysage du d\u00e9veloppement pr\u00e9clinique des m\u00e9dicaments subit un changement de paradigme majeur, motiv\u00e9 par le besoin de donn\u00e9es plus pertinentes pour l'homme et par un mouvement r\u00e9glementaire mondial en faveur de tests d'innocuit\u00e9 \u00e9thiques.","og_url":"https:\/\/www.phinc-group.com\/en\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\/","og_site_name":"PhinC Group","article_published_time":"2026-06-26T11:13:29+00:00","article_modified_time":"2026-07-20T13:04:02+00:00","og_image":[{"width":800,"height":600,"url":"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/06\/FDA-Approval-MIDD-File-e1783337522541.png","type":"image\/png"}],"author":"Mohamed Taourirt","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Mohamed Taourirt","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.phinc-group.com\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\/#article","isPartOf":{"@id":"https:\/\/www.phinc-group.com\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\/"},"author":{"name":"Mohamed Taourirt","@id":"https:\/\/www.phinc-group.com\/fr\/#\/schema\/person\/4c52ff6996589ff3ca1ec2882fc5dd0a"},"headline":"Guide de l’annonce de la FDA sur l’abandon progressif des tests sur les animaux","datePublished":"2026-06-26T11:13:29+00:00","dateModified":"2026-07-20T13:04:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.phinc-group.com\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\/"},"wordCount":1903,"publisher":{"@id":"https:\/\/www.phinc-group.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.phinc-group.com\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/06\/FDA-Approval-MIDD-File-e1783337522541.png","articleSection":["Insights"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.phinc-group.com\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\/","url":"https:\/\/www.phinc-group.com\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\/","name":"Guide de l'annonce de la FDA sur l'abandon progressif des tests sur les animaux - PhinC Group","isPartOf":{"@id":"https:\/\/www.phinc-group.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.phinc-group.com\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\/#primaryimage"},"image":{"@id":"https:\/\/www.phinc-group.com\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/06\/FDA-Approval-MIDD-File-e1783337522541.png","datePublished":"2026-06-26T11:13:29+00:00","dateModified":"2026-07-20T13:04:02+00:00","breadcrumb":{"@id":"https:\/\/www.phinc-group.com\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.phinc-group.com\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.phinc-group.com\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\/#primaryimage","url":"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/06\/FDA-Approval-MIDD-File-e1783337522541.png","contentUrl":"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/06\/FDA-Approval-MIDD-File-e1783337522541.png","width":800,"height":600},{"@type":"BreadcrumbList","@id":"https:\/\/www.phinc-group.com\/a-guide-to-the-fda-announcement-to-phase-out-animal-testing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.phinc-group.com\/en\/"},{"@type":"ListItem","position":2,"name":"Guide de l’annonce de la FDA sur l’abandon progressif des tests sur les animaux"}]},{"@type":"WebSite","@id":"https:\/\/www.phinc-group.com\/fr\/#website","url":"https:\/\/www.phinc-group.com\/fr\/","name":"PhinC Group","description":"Quantitative Pharmacology Solutions & Modeling","publisher":{"@id":"https:\/\/www.phinc-group.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.phinc-group.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.phinc-group.com\/fr\/#organization","name":"PhinC Group","url":"https:\/\/www.phinc-group.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.phinc-group.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2025\/01\/Icone-PhinC-New_white-600px.jpg","contentUrl":"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2025\/01\/Icone-PhinC-New_white-600px.jpg","width":600,"height":600,"caption":"PhinC Group"},"image":{"@id":"https:\/\/www.phinc-group.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.phinc-group.com\/fr\/#\/schema\/person\/4c52ff6996589ff3ca1ec2882fc5dd0a","name":"Mohamed Taourirt","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g","caption":"Mohamed Taourirt"},"url":"https:\/\/www.phinc-group.com\/en\/author\/mtaourirt\/"}]}},"_links":{"self":[{"href":"https:\/\/www.phinc-group.com\/en\/wp-json\/wp\/v2\/posts\/5066","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.phinc-group.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.phinc-group.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.phinc-group.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.phinc-group.com\/en\/wp-json\/wp\/v2\/comments?post=5066"}],"version-history":[{"count":24,"href":"https:\/\/www.phinc-group.com\/en\/wp-json\/wp\/v2\/posts\/5066\/revisions"}],"predecessor-version":[{"id":5105,"href":"https:\/\/www.phinc-group.com\/en\/wp-json\/wp\/v2\/posts\/5066\/revisions\/5105"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.phinc-group.com\/en\/wp-json\/wp\/v2\/media\/5071"}],"wp:attachment":[{"href":"https:\/\/www.phinc-group.com\/en\/wp-json\/wp\/v2\/media?parent=5066"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.phinc-group.com\/en\/wp-json\/wp\/v2\/categories?post=5066"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.phinc-group.com\/en\/wp-json\/wp\/v2\/tags?post=5066"},{"taxonomy":"service-associe","embeddable":true,"href":"https:\/\/www.phinc-group.com\/en\/wp-json\/wp\/v2\/service-associe?post=5066"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}